Scarica l'app Stockscreener
27.61
0.65%
-0.18
Dopo l'orario di chiusura:
27.18
-0.43
-1.56%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HRMY Giù?
Forum
Previsione
Precedente Chiudi:
$27.79
Aprire:
$27.79
Volume 24 ore:
478.66K
Relative Volume:
0.57
Capitalizzazione di mercato:
$1.60B
Reddito:
$868.45M
Utile/perdita netta:
$158.69M
Rapporto P/E:
10.19
EPS:
2.7087
Flusso di cassa netto:
$328.64M
1 W Prestazione:
-2.54%
1M Prestazione:
-23.33%
6M Prestazione:
-14.76%
1 anno Prestazione:
-15.62%
Intervallo 1D:
$27.20
$27.93
Intervallo di 1 settimana:
$27.20
$29.00
Portata 52W:
$25.52
$40.87
Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile
Nome
Harmony Biosciences Holdings Inc
Settore
Industria
Telefono
(484) 539-9800
Indirizzo
630 W GERMANTOWN PIKE, PLYMOUTH MEETING
Compare HRMY vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HRMY
Harmony Biosciences Holdings Inc
|
27.61 | 1.60B | 868.45M | 158.69M | 328.64M | 2.7087 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-23 | Downgrade | Deutsche Bank | Buy → Hold |
| 2026-02-23 | Downgrade | Truist | Buy → Hold |
| 2026-02-11 | Ripresa | UBS | Neutral |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2025-06-02 | Ripresa | Oppenheimer | Outperform |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-12-17 | Iniziato | H.C. Wainwright | Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-09-10 | Iniziato | UBS | Buy |
| 2024-06-21 | Iniziato | Citigroup | Buy |
| 2024-01-02 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-09-25 | Downgrade | Goldman | Neutral → Sell |
| 2023-09-07 | Iniziato | Berenberg | Buy |
| 2023-04-20 | Iniziato | BofA Securities | Neutral |
| 2022-10-14 | Aggiornamento | Janney | Neutral → Buy |
| 2022-10-14 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-08-03 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-13 | Downgrade | Goldman | Buy → Neutral |
| 2022-07-07 | Iniziato | Mizuho | Buy |
| 2022-04-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-12-01 | Iniziato | Oppenheimer | Outperform |
| 2021-11-04 | Iniziato | Raymond James | Outperform |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-03-29 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-09-14 | Iniziato | Goldman | Neutral |
| 2020-09-14 | Iniziato | Jefferies | Buy |
| 2020-09-14 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Harmony Biosciences Holdings Inc Borsa (HRMY) Ultime notizie
HRMY SEC FilingsHarmony Biosciences Holdings, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Valuation Update: Can Harmony Biosciences Holdings Inc reach all time highs this yearVolume Spike & Verified Stock Trade Ideas - baoquankhu1.vn
Harmony’s next-gen narcolepsy drug advances with surprising new results - MSN
Harmony Biosciences Holdings, Inc. (HRMY) Misses Q2 Earnings and Revenue Estimates - MSN
Harmony Biosciences Reports 2025 Revenue Growth, Issues 2026 Outlook - MyChesCo
Harmony Biosciences to report Q4 and full-year 2025 results - MSN
HARMONY BIOSCIENCES HOLDINGS, INC. (HRMY) - MSN
HC Wainwright & Co. Maintains Harmony Biosciences Holdings (HRMY) Buy Recommendation - MSN
Harmony Biosciences Holdings, Inc. $HRMY Shares Acquired by American Century Companies Inc. - MarketBeat
Does Mixed Q4 Results and Reaffirmed WAKIX Guidance Change The Bull Case For Harmony Biosciences (HRMY)? - simplywall.st
Harmony Biosciences Eyes Blockbuster Future After Record Year - TipRanks
HRMY Technical Analysis & Stock Price Forecast - Intellectia AI
Harmony Biosciences to Participate in Upcoming Investor Conferences - pharmiweb.com
Harmony Biosciences Holdings, Inc. (HRMY): Investor Outlook on Its Promising 45% Upside Potential - DirectorsTalk Interviews
HRMY Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
HC Wainwright Issues Pessimistic Forecast for HRMY Earnings - MarketBeat
Deutsche Bank Cuts PT on Harmony Biosciences Holdings (HRMY) to $30 From $31 - Bitget
Harmony Biosciences (NASDAQ:HRMY) Downgraded by Wall Street Zen to Hold - MarketBeat
A Look At Harmony Biosciences (HRMY) Valuation After Guidance Reaffirmation And New Pediatric WAKIX Approval - Sahm
MSN - MSN
Harmony Biosciences Downgrades Put Wakix Patent Risks In Sharp Focus - Yahoo Finance
HC Wainwright Issues Negative Estimate for HRMY Earnings - MarketBeat
Harmony Biosciences (NASDAQ:HRMY) Stock Rating Lowered by Zacks Research - MarketBeat
US applications for jobless aid rose modestly to 212,000 last week as layoffs remain at historically healthy levels - Bitget
Safe Bulkers, Inc. to Participate in the Dry Bulk Shipping Panel at the DNB Carnegie Energy & Shipping Conference in Oslo - Bitget
Truist Securities Downgrades Harmony Biosciences Holdings, Inc. (HRMY) to Hold After Patent Trial Developments - Yahoo Finance
Harmony Biosciences (HRMY) Is Down 20.1% After Reaffirming WAKIX Outlook and Winning Pediatric Approval - simplywall.st
20 Best Investments in 2026 - Insider Monkey
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
UBS Group Lowers Harmony Biosciences (NASDAQ:HRMY) Price Target to $36.00 - MarketBeat
Harmony Biosciences (HRMY): UBS Lowers Price Target to $36 | HRM - GuruFocus
HC Wainwright Reiterates Buy Rating for HRMY with $55 Target | H - GuruFocus
Harmony Biosciences' (HRMY) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
BEAM's Q4 Loss Narrower Than Expected, Revenues Rise Y/Y - Finviz
RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up - Finviz
Repligen's Q4 Earnings Beat Estimates, Revenues Surge Y/Y - Finviz
Corcept's Q4 Earnings and Revenues Fall Short of Estimates - Finviz
Analysts Offer Insights on Healthcare Companies: ProQR (PRQR), Immunic (IMUX) and Harmony Biosciences Holdings (HRMY) - The Globe and Mail
UBS cuts Harmony Biosciences stock price target on earlier Wakix generic entry - Investing.com
Harmony Biosciences Holdings, Inc. Experiences Revision in Its Stock Evaluation Amid Market Volatility - Markets Mojo
Bank of America Lowers Harmony Biosciences (NASDAQ:HRMY) Price Target to $28.00 - MarketBeat
Needham & Company LLC Issues Pessimistic Forecast for Harmony Biosciences (NASDAQ:HRMY) Stock Price - MarketBeat
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q4 2025 Earnings Call Transcript - Insider Monkey
Deutsche Bank Adjusts Harmony Biosciences PT to $30 From $31, Maintains Hold Rating - marketscreener.com
Harmony Biosciences Holdings Inc. (HRMY) PT Lowered to $36 at UBS - StreetInsider
CAVA Group To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
B of A Securities Lowers Harmony Biosciences (HRMY) Price Target to $28 | HRMY Stock News - GuruFocus
Truist reiterates Hold on Harmony Biosciences stock, sets $25 target - Investing.com Australia
Harmony Biosciences price target lowered to $28 from $32 at BofA - TipRanks
Decoding Harmony Biosciences Holdings Inc (HRMY): A Strategic SW - GuruFocus
Harmony Biosciences (HRMY) Margin Compression In FY 2025 Tests Bullish Profitability Narrative - simplywall.st
Harmony Biosciences Holdings Inc Azioni (HRMY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):